NESHER TECHNOLOGIES INC.

www.neshertech.com

ALEX: single-molecule detection platform for smarter diagnostics and cutting-edge biomedical research

Nesher Technologies Inc. (NTI) commercializes a proprietary single-molecule biodetection technology with exquisite multiplexing potential and minimal sample requirements. Using multicolor alternating-laser excitation (ALEX) fluorescence spectroscopy, it permits implementation of smFRET-based barcoding.

The competitive advantages of the disruptive ALEX technology—large multiplexing capability for simultaneous analysis of numerous targets (e.g., proteins and nucleic acids), simplified assay procedures, accurate target quantification, and rapid processing and analysis—make ALEX ideal for next-generation *in vitro* diagnostic applications. The ability to interrogate multiple biomarkers in panels maximizes the amount of clinically relevant information retrievable from minute patient samples.

The technology's capability to monitor molecular dynamics and interactions at the single-molecule level offers unprecedented ways to better understand disease-relevant biomolecular mechanisms and find new cures. It can greatly aid studies of structure-activity relationships (SAR) for drug discovery and lead optimization, opening new avenues for structure-guided rational drug design. NTI seeks Series A venture capital and/or corporate partners.

contact

Armin Reitmair, CEO
Nesher Technologies Inc.
Los Angeles, California, USA
Tel: +1-949-697-8439
Email: areitmair@neshertech.com